Sand Grove Capital Management LLP Chinook Therapeutics, Inc. Transaction History
Sand Grove Capital Management LLP
- $248 Million
- Q3 2024
Shares
1 transactions
Others Institutions Holding KDNY
# of Institutions
5Shares Held
234KCall Options Held
0Put Options Held
0-
Tekla Capital Management LLC151KShares$00.23% of portfolio
-
Health Cor Management, L.P. New York, NY60KShares$01.49% of portfolio
-
Pictet Asset Management Sa Geneva 73, V822.8KShares$00.0% of portfolio
-
Farther Finance Advisors, LLC San Francisco, CA100Shares$00.0% of portfolio
-
Parallel Advisors, LLC5Shares$00.0% of portfolio
About CHINOOK THERAPEUTICS, INC.
- Ticker KDNY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 62,896,300
- Description
- Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. ...